Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: GlobeNewswire
Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancerReported progress across OP-1250 clinical development program, including selection of the recommended Phase 2 dose, initiation of Phase 2 monotherapy enrollment, and continued dose escalation in Phase 1b combination with palbociclibCompany expects to present updated monotherapy and initial combination data in Q4 2022Strong cash, cash equivalents and marketable securities position of $240.7 million as of June 30, 2022, sufficient to support execution of clinical, research and operational goals into the second half of 2024 SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported second quarter financial results for the period ended June 30, 2022, and
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- FATE, ALPN and RLAY are among after hour movers [Seeking Alpha]Seeking Alpha
- Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceGlobeNewswire
- Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]Yahoo! Finance
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $24.00 price target on the stock.MarketBeat
OLMA
Earnings
- 3/11/24 - In-Line
OLMA
Sec Filings
- 3/29/24 - Form 4
- 3/28/24 - Form 144
- 3/22/24 - Form SC
- OLMA's page on the SEC website